BioNanoGel

BioNanoGel develops an injectable hydrogel that carries corticosteroids and analgesics and releases them over several weeks. The gel contains nanoparticles as drug carriers, enabling localized, sustained delivery for about four weeks. Target indications are chronic sinusitis, bladder pain syndrome and stress urinary incontinence—common, related conditions with high healthcare costs. By avoiding short‑acting oral medication and invasive surgery, the approach seeks to reduce admissions, lavages and burden on patients. Production uses flow chemistry to make particles efficiently, reducing space, energy and chemical inputs.
If successful, the project promises a less invasive standard of care and lower costs despite rising prevalence in an ageing population. The innovation also supports environmental goals through reduced use of medicines, excipients and energy.
Lead partner: BioMed Elements B.V. Total estimated project costs: € 3,067,244.95.

Consortium partners

• Germany: INVITE GmbH; OxProtect GmbH; Universität Münster.
• Netherlands: BioMed Elements B.V. (Lead); Noviotissue B.V.; Sure Laboratories B.V.; Radboud universitair medisch centrum / Radboudumc

See also: News - BioMed Elements